Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

Don’t fret shareholders, dividends wool come
Primary Sector

Don’t fret shareholders, dividends wool come

Listed wool company Bremworth held its annual meeting in Auckland this week.

Rakon spent additional $1.7m on acquisition costs
Markets

Rakon spent additional $1.7m on acquisition costs

Less investment in new mobile networks saw Rakon cut headcount by 22%.

NZ sharemarket rises 0.7% on back of OCR cut
Markets Market close

NZ sharemarket rises 0.7% on back of OCR cut

The S&P/NZX 50 Index closed at 13,212.92, up 99.16 points or 0.76%.

Graham Skellern 27 Nov 2024